Structural mean models for instrumented difference-in-differences

TL;DR

This paper introduces novel multiplicative structural mean models for instrumented difference-in-differences, enabling the estimation of treatment effects on count and rare binary outcomes with valid instruments.

Contribution

It proposes new models for instrumented difference-in-differences that handle count and rare binary outcomes, with semi-parametric estimation and machine learning integration.

Findings

Applied models to healthcare data on antihyperglycemic drugs

Estimated treatment effects on weight gain outcomes

Demonstrated model flexibility and efficiency

Abstract

In the standard difference-in-differences research design, the parallel trends assumption may be violated when the relationship between the exposure trend and the outcome trend is confounded by unmeasured confounders. Progress can be made if there is an exogenous variable that (i) does not directly influence the change in outcome means (i.e. the outcome trend) except through influencing the change in exposure means (i.e. the exposure trend), and (ii) is not related to the unmeasured exposure - outcome confounders on the trend scale. Such exogenous variable is called an instrument for difference-in-differences. For continuous outcomes that lend themselves to linear modelling, so-called instrumented difference-in-differences methods have been proposed. In this paper, we will suggest novel multiplicative structural mean models for instrumented difference-in-differences, which allow one to identify and estimate the average treatment effect on count and rare binary outcomes, in the whole population or among the treated, when a valid instrument for difference-in-differences is available. We discuss the identifiability of these models, then develop efficient semi-parametric estimation approaches that allow the use of flexible, data-adaptive or machine learning methods to estimate the nuisance parameters. We apply our proposal on health care data to investigate the risk of moderate to severe weight gain under sulfonylurea treatment compared to metformin treatment, among new users of antihyperglycemic drugs.